31 Bowen’s disease and erythroplasia of Queyrat Thomas D. Regan and Naomi Lawrence Evidence Levels: A Double-blind study B Clinical trial ≥ 20 subjects C Clinical trial < 20 subjects D Series ≥ 5 subjects E Anecdotal case reports Bowen’s disease and erythroplasia of Queyrat (EQ) are defined as intraepidermal squamous cell carcinoma, the latter occurring on the penis. The clinical appearance is that of a sharply demarcated, erythematous plaque that is persistent and slowly enlarging. Risk factors for the development of Bowen’s disease and EQ vary according to the site of disease, but generally include sun exposure, HPV (human papilloma virus) infection, arsenic exposure, radiation exposure, and HIV or other forms of immunosuppression. Management strategy The goals of treatment in both Bowen’s disease and EQ are cure and prevention of progression to invasive squamous cell carcinoma, while maintaining function and cosmesis. Invasive transformation of EQ is more common (10%) and metastasizes earlier than Bowen’s disease (3%). Multiple treatment options are available and no one treatment is ideal for all situations. Definitive treatment is surgical excision if the lesion is small and well defined. Mohs micrographic surgery (MMS) is recommended in the treatment of larger, ill-defined lesions, especially when preservation of normal tissue is crucial, as with EQ. Surgical ablation may be achieved with electrodesiccation and curettage, cryotherapy, or laser. Non-surgical options include imiquimod cream (a topical immunomodulator), topical 5-fluorouracil (5-FU), photodynamic therapy (PDT), and radiation therapy. Standard of care requires that a follow-up period of no less than 5 years be observed to claim clinical cure of Bowen’s disease and EQ. Therefore, the extremely brief duration of follow-up for many studies is inadequate. Specific investigations Skin biopsy Dermoscopy Immunoperoxidase studies for human papillomavirus Dermoscopy of Bowen’s disease. Zalaudek I, Argenziano G, Leinweber B, Citarella L, Hofmann-Wellenhof R, et al. Br J Dermatol 2004; 150: 1112–16. The small sample size limits the application of this newly described diagnostic tool. The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. Iftner A, Klug SJ, Garbe C, Blum A, Blum A, Stancu A, et al. Cancer Res 2003; 63: 7515–19. The study found an odds ratio of 59 (95% confidence interval 5.4–645) for non-melanoma skin cancer in patients who were DNA positive for the high-risk mucosal HPV types 16, 31, 35, and 51. First-line therapies Standard excision B Mohs micrographic surgery B Cutaneous squamous carcinoma in situ (Bowen’s disease): treatment with Mohs micrographic surgery. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. J Am Acad Dermatol 2005; 52: 997–1002. A case series evaluating 270 cases of Bowen’s disease treated with MMS with 5-year follow-up demonstrating recurrence rates of approximately 6%. The majority of lesions treated were on the head and neck, and many were recurrent at the time of MMS. Only gold members can continue reading. Log In or Register to continue Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window) Related Related posts: Discoid lupus erythematosus Mucoceles Tinea capitis Herpes genitalis Necrolytic migratory erythema Nevoid basal cell carcinoma syndrome Stay updated, free articles. Join our Telegram channel Join Tags: Treatment of Skin Disease Comprehensive Therapeutic Strategies Aug 7, 2016 | Posted by admin in Dermatology | Comments Off on Bowen’s disease and erythroplasia of Queyrat Full access? Get Clinical Tree Get Clinical Tree app for offline access Get Clinical Tree app for offline access
31 Bowen’s disease and erythroplasia of Queyrat Thomas D. Regan and Naomi Lawrence Evidence Levels: A Double-blind study B Clinical trial ≥ 20 subjects C Clinical trial < 20 subjects D Series ≥ 5 subjects E Anecdotal case reports Bowen’s disease and erythroplasia of Queyrat (EQ) are defined as intraepidermal squamous cell carcinoma, the latter occurring on the penis. The clinical appearance is that of a sharply demarcated, erythematous plaque that is persistent and slowly enlarging. Risk factors for the development of Bowen’s disease and EQ vary according to the site of disease, but generally include sun exposure, HPV (human papilloma virus) infection, arsenic exposure, radiation exposure, and HIV or other forms of immunosuppression. Management strategy The goals of treatment in both Bowen’s disease and EQ are cure and prevention of progression to invasive squamous cell carcinoma, while maintaining function and cosmesis. Invasive transformation of EQ is more common (10%) and metastasizes earlier than Bowen’s disease (3%). Multiple treatment options are available and no one treatment is ideal for all situations. Definitive treatment is surgical excision if the lesion is small and well defined. Mohs micrographic surgery (MMS) is recommended in the treatment of larger, ill-defined lesions, especially when preservation of normal tissue is crucial, as with EQ. Surgical ablation may be achieved with electrodesiccation and curettage, cryotherapy, or laser. Non-surgical options include imiquimod cream (a topical immunomodulator), topical 5-fluorouracil (5-FU), photodynamic therapy (PDT), and radiation therapy. Standard of care requires that a follow-up period of no less than 5 years be observed to claim clinical cure of Bowen’s disease and EQ. Therefore, the extremely brief duration of follow-up for many studies is inadequate. Specific investigations Skin biopsy Dermoscopy Immunoperoxidase studies for human papillomavirus Dermoscopy of Bowen’s disease. Zalaudek I, Argenziano G, Leinweber B, Citarella L, Hofmann-Wellenhof R, et al. Br J Dermatol 2004; 150: 1112–16. The small sample size limits the application of this newly described diagnostic tool. The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. Iftner A, Klug SJ, Garbe C, Blum A, Blum A, Stancu A, et al. Cancer Res 2003; 63: 7515–19. The study found an odds ratio of 59 (95% confidence interval 5.4–645) for non-melanoma skin cancer in patients who were DNA positive for the high-risk mucosal HPV types 16, 31, 35, and 51. First-line therapies Standard excision B Mohs micrographic surgery B Cutaneous squamous carcinoma in situ (Bowen’s disease): treatment with Mohs micrographic surgery. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. J Am Acad Dermatol 2005; 52: 997–1002. A case series evaluating 270 cases of Bowen’s disease treated with MMS with 5-year follow-up demonstrating recurrence rates of approximately 6%. The majority of lesions treated were on the head and neck, and many were recurrent at the time of MMS. Only gold members can continue reading. Log In or Register to continue Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window) Related Related posts: Discoid lupus erythematosus Mucoceles Tinea capitis Herpes genitalis Necrolytic migratory erythema Nevoid basal cell carcinoma syndrome Stay updated, free articles. Join our Telegram channel Join Tags: Treatment of Skin Disease Comprehensive Therapeutic Strategies Aug 7, 2016 | Posted by admin in Dermatology | Comments Off on Bowen’s disease and erythroplasia of Queyrat Full access? Get Clinical Tree